Phathom Pharmaceuticals (PHAT) Receivables: 2023-2025
Historic Receivables for Phathom Pharmaceuticals (PHAT) over the last 2 years, with Sep 2025 value amounting to $55.8 million.
- Phathom Pharmaceuticals' Receivables rose 165.01% to $55.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.2 million, marking a year-over-year increase of 386.59%. This contributed to the annual value of $38.8 million for FY2024, which is 2270.01% up from last year.
- Per Phathom Pharmaceuticals' latest filing, its Receivables stood at $55.8 million for Q3 2025, which was up 8.85% from $51.3 million recorded in Q2 2025.
- Phathom Pharmaceuticals' Receivables' 5-year high stood at $55.8 million during Q3 2025, with a 5-year trough of $1.6 million in Q4 2023.
- Over the past 3 years, Phathom Pharmaceuticals' median Receivables value was $28.7 million (recorded in 2024), while the average stood at $27.5 million.
- Data for Phathom Pharmaceuticals' Receivables shows a peak YoY surged of 2,270.01% (in 2024) over the last 5 years.
- Phathom Pharmaceuticals' Receivables (Quarterly) stood at $1.6 million in 2023, then skyrocketed by 2,270.01% to $38.8 million in 2024, then surged by 165.01% to $55.8 million in 2025.
- Its Receivables stands at $55.8 million for Q3 2025, versus $51.3 million for Q2 2025 and $36.4 million for Q1 2025.